Natera, Inc. (NASDAQ:NTRA) Given Average Rating of “Buy” by Brokerages

Shares of Natera, Inc. (NASDAQ:NTRAGet Free Report) have earned a consensus recommendation of “Buy” from the twelve analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $71.54.

A number of brokerages have recently commented on NTRA. Raymond James upgraded shares of Natera from an “outperform” rating to a “strong-buy” rating and set a $68.00 price target on the stock in a report on Monday, November 13th. Piper Sandler dropped their target price on shares of Natera from $80.00 to $70.00 and set an “overweight” rating on the stock in a report on Monday, October 16th. Morgan Stanley dropped their target price on shares of Natera from $70.00 to $68.00 and set an “overweight” rating on the stock in a report on Friday, November 10th. Guggenheim started coverage on shares of Natera in a report on Thursday, December 14th. They issued a “buy” rating and a $70.00 target price on the stock. Finally, TD Cowen boosted their target price on shares of Natera from $82.00 to $87.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th.

View Our Latest Research Report on NTRA

Natera Price Performance

Shares of NASDAQ:NTRA opened at $70.97 on Thursday. The firm has a market cap of $8.53 billion, a PE ratio of -15.70 and a beta of 1.34. The firm’s fifty day moving average is $63.25 and its 200-day moving average is $54.24. The company has a debt-to-equity ratio of 0.36, a quick ratio of 4.23 and a current ratio of 4.37. Natera has a 52 week low of $36.90 and a 52 week high of $71.29.

Insider Transactions at Natera

In other news, CFO Michael Burkes Brophy sold 34,029 shares of the business’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $70.03, for a total transaction of $2,383,050.87. Following the completion of the sale, the chief financial officer now directly owns 70,646 shares of the company’s stock, valued at $4,947,339.38. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Michael Burkes Brophy sold 34,029 shares of the business’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $70.03, for a total transaction of $2,383,050.87. Following the completion of the sale, the chief financial officer now directly owns 70,646 shares of the company’s stock, valued at $4,947,339.38. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gail Boxer Marcus sold 1,000 shares of the company’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $54.31, for a total transaction of $54,310.00. Following the completion of the sale, the director now directly owns 20,646 shares of the company’s stock, valued at $1,121,284.26. The disclosure for this sale can be found here. Insiders sold a total of 752,272 shares of company stock valued at $45,019,103 over the last three months. Corporate insiders own 9.42% of the company’s stock.

Institutional Investors Weigh In On Natera

Institutional investors have recently added to or reduced their stakes in the company. C WorldWide Group Holding A S grew its position in Natera by 11.8% in the 3rd quarter. C WorldWide Group Holding A S now owns 475,000 shares of the medical research company’s stock worth $21,019,000 after purchasing an additional 50,000 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in Natera in the 3rd quarter worth about $376,000. Bank of New York Mellon Corp boosted its stake in Natera by 3.0% in the second quarter. Bank of New York Mellon Corp now owns 404,659 shares of the medical research company’s stock valued at $19,691,000 after acquiring an additional 11,948 shares during the last quarter. Braidwell LP boosted its stake in Natera by 17.4% in the second quarter. Braidwell LP now owns 1,152,851 shares of the medical research company’s stock valued at $56,098,000 after acquiring an additional 170,610 shares during the last quarter. Finally, National Bank of Canada FI purchased a new position in Natera in the third quarter valued at about $1,932,000. 92.59% of the stock is owned by institutional investors.

Natera Company Profile

(Get Free Report

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Further Reading

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.